Hood River Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Hood River Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$62.8M	Buy	371,503 +5,327	+1%	+$920K	0.63%	53
2025 Q4	$66.9M	Buy	366,176 +6,219	+2%	+$868K	0.73%	53
2025 Q3	$43.7M	Sell	359,957 -11,147	-3%	-$1.26M	0.52%	67
2025 Q2	$38.7M	Buy	+371,104	New	+$39.3M	0.54%	65
2025 Q1	–	Sell	-644,785	Closed	-$54.6M	–	147
2024 Q4	$54.6M	Buy	644,785 +19,701	+3%	+$1.81M	0.81%	45
2024 Q3	$56.2M	Buy	625,084 +76,018	+14%	+$6.64M	0.91%	42
2024 Q2	$44.2M	Buy	549,066 +28,316	+5%	+$2.1M	0.92%	38
2024 Q1	$41.6M	Buy	520,750 +127,997	+33%	+$10.7M	0.93%	39
2023 Q4	$31.3M	Buy	392,753 +9,477	+2%	+$634K	0.86%	46
2023 Q3	$26.8M	Sell	383,276 -1,085	-0.3%	-$81.1K	0.86%	51
2023 Q2	$27.6M	Buy	384,361 +3,539	+0.9%	+$261K	0.82%	55
2023 Q1	$23.5M	Sell	380,822 -79,473	-17%	-$5.22M	0.76%	51
2022 Q4	$35.5M	Buy	+460,295	New	+$27.5M	1.29%	29

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hood River Capital Management's AXSM Position: Q1 2026 in Review

Hood River Capital Management increased its Axsome Therapeutics (AXSM) stake by 1.5% in Q1 2026, buying an estimated $920K and bringing the position to 371,503 shares worth $62.8M. The position accounts for 0.63% of the portfolio, ranked #53.

Hood River Capital Management first reported a position in AXSM in Q4 2022 and has held it in 13 quarters since. The position peaked at $66.9M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Hood River Capital Management held 371,503 shares of Axsome Therapeutics worth $62.8M as of Q1 2026.
Hood River Capital Management bought 5,327 Axsome Therapeutics shares in Q1 2026, an estimated $920K.
Axsome Therapeutics made up 0.63% of Hood River Capital Management's portfolio in Q1 2026, its #53 holding.
Hood River Capital Management first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 13 quarters since.
Hood River Capital Management's Axsome Therapeutics position peaked at $66.9M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Hood River Capital Management's 13F filing for Q1 2026, filed 15 May 2026.